Cargando…
A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines
BACKGROUND: Since 2020, over 250 million doses of mRNA-based SARS-CoV-2 vaccines have been administered in the United States and hundreds of millions worldwide between the Pfizer-BioNTech and Moderna SARS-CoV-2 vaccines. To date, there have been rare reports associating mRNA-based SARS-CoV-2 vaccine...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908032/ https://www.ncbi.nlm.nih.gov/pubmed/35280277 http://dx.doi.org/10.3389/fneur.2022.796882 |
_version_ | 1784665786728579072 |
---|---|
author | Ballout, Ahmad A. Babaie, Anna Kolesnik, Michael Li, Jian Yi Hameed, Natasha Waldman, Glenn Chaudhry, Frasat Saba, Sami Harel, Asaff Najjar, Souhel |
author_facet | Ballout, Ahmad A. Babaie, Anna Kolesnik, Michael Li, Jian Yi Hameed, Natasha Waldman, Glenn Chaudhry, Frasat Saba, Sami Harel, Asaff Najjar, Souhel |
author_sort | Ballout, Ahmad A. |
collection | PubMed |
description | BACKGROUND: Since 2020, over 250 million doses of mRNA-based SARS-CoV-2 vaccines have been administered in the United States and hundreds of millions worldwide between the Pfizer-BioNTech and Moderna SARS-CoV-2 vaccines. To date, there have been rare reports associating mRNA-based SARS-CoV-2 vaccines with episodes of inflammatory and autoimmune CNS disorders. We report a case series of five patients with new-onset neurological disorders of inflammatory or immunological origin temporally associated with these vaccines. METHODS: A case-series of five patients within a single 23-hospital health system who developed new-onset CNS inflammatory disease within 2 weeks of receiving a dose of an mRNA-based SARS-CoV-2 vaccine. RESULTS: Five cases of post-vaccination CNS disorders of immune origin (fatal ADEM; n = 1, new-onset NMOSD; n = 2, new-clinical onset MS-like syndrome but with preexisting clinically silent mild demyelination; n = 1, meningoencephalitis; n = 1) observed within 2 weeks of inoculation with either the first or second dose of mRNA-based SARS-CoV-2 vaccines (Moderna = 3, Pfizer = 2). DISCUSSION: To our knowledge, these are among the emerging cases of CNS adverse events of immunological or inflammatory origin. These findings should be interpreted with great caution as they neither prove a mechanistic link nor imply a potential long-term increased risk in post-vaccination CNS autoimmunity. Larger prospective studies assessing the potential association between mRNA-based vaccination and the development of neurological adverse events of suspected immune origin, particularly among those with underlying CNS or systemic autoimmune disorders, are needed. The use of mRNA-based SARS-CoV-2 vaccines should continue to be strongly encouraged given their high efficacy in overcoming this pandemic. |
format | Online Article Text |
id | pubmed-8908032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89080322022-03-11 A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines Ballout, Ahmad A. Babaie, Anna Kolesnik, Michael Li, Jian Yi Hameed, Natasha Waldman, Glenn Chaudhry, Frasat Saba, Sami Harel, Asaff Najjar, Souhel Front Neurol Neurology BACKGROUND: Since 2020, over 250 million doses of mRNA-based SARS-CoV-2 vaccines have been administered in the United States and hundreds of millions worldwide between the Pfizer-BioNTech and Moderna SARS-CoV-2 vaccines. To date, there have been rare reports associating mRNA-based SARS-CoV-2 vaccines with episodes of inflammatory and autoimmune CNS disorders. We report a case series of five patients with new-onset neurological disorders of inflammatory or immunological origin temporally associated with these vaccines. METHODS: A case-series of five patients within a single 23-hospital health system who developed new-onset CNS inflammatory disease within 2 weeks of receiving a dose of an mRNA-based SARS-CoV-2 vaccine. RESULTS: Five cases of post-vaccination CNS disorders of immune origin (fatal ADEM; n = 1, new-onset NMOSD; n = 2, new-clinical onset MS-like syndrome but with preexisting clinically silent mild demyelination; n = 1, meningoencephalitis; n = 1) observed within 2 weeks of inoculation with either the first or second dose of mRNA-based SARS-CoV-2 vaccines (Moderna = 3, Pfizer = 2). DISCUSSION: To our knowledge, these are among the emerging cases of CNS adverse events of immunological or inflammatory origin. These findings should be interpreted with great caution as they neither prove a mechanistic link nor imply a potential long-term increased risk in post-vaccination CNS autoimmunity. Larger prospective studies assessing the potential association between mRNA-based vaccination and the development of neurological adverse events of suspected immune origin, particularly among those with underlying CNS or systemic autoimmune disorders, are needed. The use of mRNA-based SARS-CoV-2 vaccines should continue to be strongly encouraged given their high efficacy in overcoming this pandemic. Frontiers Media S.A. 2022-02-24 /pmc/articles/PMC8908032/ /pubmed/35280277 http://dx.doi.org/10.3389/fneur.2022.796882 Text en Copyright © 2022 Ballout, Babaie, Kolesnik, Li, Hameed, Waldman, Chaudhry, Saba, Harel and Najjar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Ballout, Ahmad A. Babaie, Anna Kolesnik, Michael Li, Jian Yi Hameed, Natasha Waldman, Glenn Chaudhry, Frasat Saba, Sami Harel, Asaff Najjar, Souhel A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines |
title | A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines |
title_full | A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines |
title_fullStr | A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines |
title_full_unstemmed | A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines |
title_short | A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines |
title_sort | single-health system case series of new-onset cns inflammatory disorders temporally associated with mrna-based sars-cov-2 vaccines |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908032/ https://www.ncbi.nlm.nih.gov/pubmed/35280277 http://dx.doi.org/10.3389/fneur.2022.796882 |
work_keys_str_mv | AT balloutahmada asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT babaieanna asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT kolesnikmichael asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT lijianyi asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT hameednatasha asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT waldmanglenn asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT chaudhryfrasat asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT sabasami asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT harelasaff asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT najjarsouhel asinglehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT balloutahmada singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT babaieanna singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT kolesnikmichael singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT lijianyi singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT hameednatasha singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT waldmanglenn singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT chaudhryfrasat singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT sabasami singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT harelasaff singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines AT najjarsouhel singlehealthsystemcaseseriesofnewonsetcnsinflammatorydisorderstemporallyassociatedwithmrnabasedsarscov2vaccines |